Day: March 20, 2025
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
- PBGENE-HBV, the first and only clinical stage gene editing therapy for chronic hepatitis B – - Repeat dosing of PBGENE-HBV supported by definitive preclinical safety and toxicology studies - - ELIMINATE-B global Phase 1 study for chronic hepatitis B actively enrolling patients and will evaluate